Back to Search
Start Over
Efficacy and safety of amantadine for the treatment of fatigue in multiple sclerosis: a systematic review and meta-analysis.
- Source :
-
Neurodegenerative disease management [Neurodegener Dis Manag] 2020 Dec; Vol. 10 (6), pp. 383-395. Date of Electronic Publication: 2020 Oct 05. - Publication Year :
- 2020
-
Abstract
- Background: Fatigue is a debilitating symptom of multiple sclerosis (MS) affecting at least 75% of patients. Amantadine has been tested for MS-related fatigue treatment but efficacy and safety remain unclear. Materials & methods: We performed a systematic review and meta-analysis of qualified literatures searched until 30 April 2020. Results: A total of 11 clinical trials were included. The meta-analysis revealed improvement of MS-related fatigue with amantadine treatment using the patients' subjective responses and validated fatigue scales. Conclusion: Amantadine is the most studied drug that has shown improvement of MS-related fatigue, with mild side effects and good tolerability. Larger studies using a standard measurement for MS-related fatigue are recommended to improve the quality of evidence. Safety and efficacy on long-term use needs further investigation.
Details
- Language :
- English
- ISSN :
- 1758-2032
- Volume :
- 10
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Neurodegenerative disease management
- Publication Type :
- Academic Journal
- Accession number :
- 33012266
- Full Text :
- https://doi.org/10.2217/nmt-2020-0030